N. Viney

发表

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data

M. Benson, Shuling Guo, B. Monia, 2020, ESC heart failure.

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Richard G. Lee, S. Crooke, M. Graham, 2013, Circulation research.

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.

J. Tardif, E. Steinhagen-Thiessen, J. Witztum, 2020, The New England journal of medicine.

Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen.

J. Witztum, S. Tsimikas, S. Marcovina, 2021, Atherosclerosis.

Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans

M. Graham, R. Crooke, S. Tsimikas, 2016, Journal of Lipid Research.

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

J. Witztum, M. Graham, R. Crooke, 2015, The Lancet.

Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials.

J. Witztum, S. Tsimikas, S. Marcovina, 2017, Journal of clinical lipidology.

Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis[S]

M. Boffa, M. Koschinsky, J. Witztum, 2019, Journal of Lipid Research.

Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size.

J. Witztum, S. Tsimikas, S. Fazio, 2018, Journal of clinical lipidology.

Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.

J. Witztum, S. Tsimikas, S. Xia, 2018, Journal of clinical lipidology.

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

D. Gaudet, J. Kastelein, D. Brisson, 2015, The New England journal of medicine.

Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

W. Litchy, M. Benson, P. Dyck, 2021, Neurology and Therapy.

Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience

S. Crooke, B. Baker, R. Yu, 2019, Nucleic acid therapeutics.

Liver‐directed drugs for transthyretin‐mediated amyloidosis

M. Maurer, B. Baker, M. Fontana, 2022, Journal of the peripheral nervous system : JPNS.

INTRAGASTRIC ACIDITY, BACTERIA, NITRITE, AND N-NITROSO COMPOUNDS BEFORE, DURING, AND AFTER CIMETIDINE TREATMENT

R. Hunt, N. Lightfoot, Z. Ahmet, 1982, The Lancet.

IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production

B. Monia, B. Baker, A. Macleod, 2019, Nucleic acid therapeutics.

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

S. Crooke, J. Witztum, E. Stroes, 2016, The Lancet.

Total nitroso compounds in gastric juice.

N. Viney, P. Bavin, D. Darkin, 1982, IARC scientific publications.

Epidemic hypochlorhydria.

R. Hunt, N. Lightfoot, B. Addis, 1985, British medical journal.

Abstract 14196: Evaluation of Isis Apo(a)Rx, an Antisense Inhibitor to Apolipoprotein(a), in Healthy Volunteers

M. Graham, R. Crooke, N. Viney, 2013 .

Phase 1 Investigation of a Ligand-Conjugated Antisense Oligonucleotide with Increased Potency for the Treatment of Transthyretin Amyloidosis

Shuling Guo, B. Monia, B. Baker, 2019, Journal of Cardiac Failure.

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Richard G. Lee, S. Crooke, M. Graham, 2013, Circulation research.

Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema.

E. Stroes, M. Levi, B. Baker, 2020, The New England journal of medicine.

Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

R. Falk, M. Benson, B. Monia, 2019, Blood.